In Silico Screening and Testing of FDA-Approved Small Molecules to Block SARS-CoV-2 Entry to the Host Cell by Inhibiting Spike Protein Cleavage

The COVID-19 pandemic began in 2019, but it is still active. The development of an effective vaccine reduced the number of deaths; however, a treatment is still needed. Here, we aimed to inhibit viral entry to the host cell by inhibiting spike (S) protein cleavage by several proteases. We developed...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozdemir, E. Sila, Le, Hillary H., Yildirim, Adem, Ranganathan, Srivathsan V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9231362/
https://www.ncbi.nlm.nih.gov/pubmed/35746605
http://dx.doi.org/10.3390/v14061129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9231362/
https://www.ncbi.nlm.nih.gov/pubmed/35746605
http://dx.doi.org/10.3390/v14061129

Ejemplares similares